logo-loader
viewNeovasc

Neovasc filing for a CE mark approval in Europe in 2020

Neovasc Inc. (NASDAQ:NVCN) (TSX: NVCN) CEO Fred Colen sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Vancouver, Canada-based company develops, manufactures and markets medical device products for the cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina.

Quick facts: Neovasc

Price: 3.41 CAD

TSX:NVCN
Market: TSX
Market Cap: $60.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpine 4 Technologies growth continues in Q-1 of 2020 with a nice jump in...

Alpine 4 Technologies (OTC: ALPP) CEO Kent Wilson joined Steve Darling from Proactive Vancouver to share news about the company’s 1st Quarter financial numbers that some very good growth. Wilson shares the numbers and some of the highlights. Wilson also talked about the company’s strategy when...

9 hours, 59 minutes ago

2 min read